Evidence map›Paper›PMID 41942708›Full record

ReviewCardiovascular and interventional radiology2026

Meta-Analysis: The Holy Grail?

Danielle J W Vos, Hannah H Schulz, Martijn R Meijerink

Abstract readReview
In one paragraph

Review in Cardiovascular and interventional radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Danielle J W VosAmsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
Hannah H SchulzAmsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands. h.h.schulz@amsterdamumc.nl.
Martijn R MeijerinkAmsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionMeta-analysis is often regarded as a cornerstone of evidence synthesis, yet its application in interventional oncology (IO) is challenged by heterogeneous study designs, rapidly evolving technologies, and limited availability of randomized controlled trials. This review evaluates the current state of evidence in IO, emphasizing the role of systematic reviews and meta-analyses in guiding clinical decision-making.

methodsTo evaluate the level of evidence of the published studies within IO, a PubMed search was conducted with the aim to identify the various article types that have been published over the past decades.

resultsOver the past decades, the number of original articles has remained relatively stable. A notable observation is the significant increase in the number of systematic reviews and meta-analyses, particularly when compared to the relatively unchanged volume of original articles. DISCUSSION: This trend suggests a growing emphasis on evaluating existing research rather than generating new prospective studies. The grading of recommendations assessment, development and evaluation (GRADE) approach to assess evidence quality, the importance of adhering to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, and common challenges like risk of bias and publication bias will be discussed within this context.

conclusionUltimately, meta-analysis should not be viewed as a definitive benchmark in IO, but as a methodological tool of which conclusions depend heavily on the quality, consistency, and relevance of the underlying studies.

Indexed as

Medical OncologyMeta-Analysis as TopicNeoplasmsEvidence-Based MedicineHumansCA: CryoablationEBM: Evidence-based medicineGRADE: Grading of recommendations assessment, development and evaluationIO: Interventional OncologyIRE: Irreversible electroporationMWA: Microwave ablationPRISMA: Preferred Reporting Items for Systematic Reviews and Meta-AnalysesRCTs: Randomized controlled trialsRFA: Radiofrequency ablationTA(C)E: Trans arterial (chemo) embolizationTARE: Transarterial radioembolization (TARE)

Identifiers

PMID41942708
PMCPMC13156232

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.